AnaptysBio和Tesaro(GSK)就Jemperli的毒品权利相互提出诉讼,审判定于2026年7月进行。 AnaptysBio and Tesaro (GSK) sue each other over Jemperli drug rights, with trial set for July 2026.

AnaptysBio起诉GSK子公司Tesaro, 指控其违反2014年癌症药物Jemperli协议, 声称Tesaro违反了排他性, 未能在商业上取得最大成功。 AnaptysBio has sued Tesaro, a GSK subsidiary, over alleged breaches of their 2014 agreement for the cancer drug Jemperli, claiming Tesaro violated exclusivity and failed to maximize commercial success. 泰萨罗反诉称,通过声称这些违规行为,阿纳普蒂斯生物违反了协议,寻求终止许可,确保永久权益,并将版权费降低50%. Tesaro countersued, alleging AnaptysBio breached the agreement by asserting those violations, seeking to terminate the license, secure a perpetual right to Jemperli, and cut royalties by 50%. 双方同意在2026年7月加快审判。 Both sides agree to an expedited trial set for July 2026. Jemperli在超过35个国家获得批准,目前正在积极研制治疗其他癌症的药物,诉讼期间应支付特许权使用费。 Jemperli, approved in over 35 countries, is under active development for other cancers, with royalty payments due during litigation.